160 related articles for article (PubMed ID: 38034969)
1. Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia.
Tosun Ç; Wallabregue ALD; Mallerman M; Phillips SE; Edwards CM; Conway SJ; Hammond EM
JACS Au; 2023 Nov; 3(11):3237-3246. PubMed ID: 38034969
[TBL] [Abstract][Full Text] [Related]
2. Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor.
Skwarska A; Calder EDD; Sneddon D; Bolland H; Odyniec ML; Mistry IN; Martin J; Folkes LK; Conway SJ; Hammond EM
Cell Chem Biol; 2021 Sep; 28(9):1258-1270.e13. PubMed ID: 33910023
[TBL] [Abstract][Full Text] [Related]
3. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
[TBL] [Abstract][Full Text] [Related]
4. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
[TBL] [Abstract][Full Text] [Related]
5. Zap-Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat.
Troelsen KS; Calder EDD; Skwarska A; Sneddon D; Hammond EM; Conway SJ
ChemMedChem; 2021 Dec; 16(24):3691-3700. PubMed ID: 34259396
[TBL] [Abstract][Full Text] [Related]
6.
Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
[TBL] [Abstract][Full Text] [Related]
7. Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.
Wang J; Guise CP; Dachs GU; Phung Y; Hsu AH; Lambie NK; Patterson AV; Wilson WR
Biochem Pharmacol; 2014 Oct; 91(4):436-46. PubMed ID: 25130546
[TBL] [Abstract][Full Text] [Related]
8. CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A.
Cazares-Körner C; Pires IM; Swallow ID; Grayer SC; O'Connor LJ; Olcina MM; Christlieb M; Conway SJ; Hammond EM
ACS Chem Biol; 2013 Jul; 8(7):1451-9. PubMed ID: 23597309
[TBL] [Abstract][Full Text] [Related]
9. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
Phillips RM
Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
[TBL] [Abstract][Full Text] [Related]
10. A novel multifunctional 2-nitroimidazole-based bioreductive linker and its application in hypoxia-activated prodrugs.
Huang Y; Jin C; Yu J; Wang L; Lu W
Bioorg Chem; 2020 Aug; 101():103975. PubMed ID: 32474180
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
[TBL] [Abstract][Full Text] [Related]
12. Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer.
Narva SI; Seppänen MP; Raiko JRH; Forsback SJ; Orte KJ; Virtanen JM; Hynninen J; Hietanen S
Clin Nucl Med; 2021 Dec; 46(12):952-957. PubMed ID: 34619699
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
Liang D; Miller GH; Tranmer GK
Curr Med Chem; 2015; 22(37):4313-25. PubMed ID: 26487420
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
Lee AE; Wilson WR
Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 - 2021.
Anduran E; Dubois LJ; Lambin P; Winum JY
Expert Opin Ther Pat; 2022 Jan; 32(1):1-12. PubMed ID: 34241566
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia in human intraperitoneal and extremity sarcomas.
Evans SM; Hahn SM; Magarelli DP; Zhang PJ; Jenkins WT; Fraker DL; Hsi RA; McKenna WG; Koch CJ
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):587-96. PubMed ID: 11173159
[TBL] [Abstract][Full Text] [Related]
17. Noncovalent Theranostic Prodrug for Hypoxia-Activated Drug Delivery and Real-Time Tracking.
Zhao XB; Gao K; Shi YP
Anal Chem; 2021 Nov; 93(45):15080-15087. PubMed ID: 34743509
[TBL] [Abstract][Full Text] [Related]
18. Prospects for bioreductive drug development.
Phillips RM
Expert Opin Investig Drugs; 1998 Jun; 7(6):905-28. PubMed ID: 15992006
[TBL] [Abstract][Full Text] [Related]
19. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.
Lord EM; Harwell L; Koch CJ
Cancer Res; 1993 Dec; 53(23):5721-6. PubMed ID: 8242628
[TBL] [Abstract][Full Text] [Related]
20. A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs.
Sun Z; Zhang H; Wu J; Gao F; Zhang C; Hu X; Liu Q; Wei Y; Zhuang J; Huang X
Mol Pharm; 2020 Jun; 17(6):2072-2082. PubMed ID: 32352301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
